Synaptogenix Inc Ordinary Shares SNPX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNPX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.56
- Day Range
- $4.41–4.60
- 52-Week Range
- $3.53–47.00
- Bid/Ask
- $4.41 / $4.59
- Market Cap
- $4.79 Mil
- Volume/Avg
- 3,503 / 45,890
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.synaptogen.com
Valuation
|
Metric
|
SNPX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.17 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SNPX
|
|---|---|
Quick Ratio | 7.04 |
Current Ratio | 7.14 |
Interest Coverage | — |
Quick Ratio
SNPX
Profitability
|
Metric
|
SNPX
|
|---|---|
Return on Assets (Normalized) | −16.44% |
Return on Equity (Normalized) | −20.19% |
Return on Invested Capital (Normalized) | −24.26% |
Return on Assets
SNPX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yhdvykqd | Ylwp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Clxqmtmn | Wclqlq | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rkfjcdt | Vrvwsg | $97.8 Bil | |
MRNA
| Moderna Inc | Mbnbbnbx | Vnd | $38.8 Bil | |
ARGX
| argenx SE ADR | Szhxsdvn | Fkx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hxczwpm | Qmr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tfcfhlty | Lsqdkrj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lpyxzmxp | Szdyzj | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Msxnlxhcrn | Ypswyr | $12.5 Bil | |
INCY
| Incyte Corp | Ztmmlpq | Lgnngj | $11.5 Bil |